Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy

The Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk (NOVOb.CO) CEO Lars Jorgensen has agreed to testify voluntarily in a hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.